AbbVie Inc. (BVMF:ABBV34)

Market Cap	2.06T
Revenue (ttm)	317.87B
Net Income (ttm)	12.51B
Shares Out	n/a
EPS (ttm)	7.04
PE Ratio	164.36
Forward PE	15.89
Dividend	1.54 (2.08%)
Ex-Dividend Date	Jan 15, 2026

Volume	277
Average Volume	1,714
Open	75.36
Previous Close	75.45
Day's Range	73.50 - 75.52
52-Week Range	60.00 - 81.36
Beta	0.35
RSI	39.91
Earnings Date	Feb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: ABBV34

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD